Results 151 to 160 of about 1,224,792 (212)

Efficacy and Safety of Sodium Oxybate in Adults With Idiopathic Hypersomnia

Neurology
Background and Objectives Idiopathic hypersomnia (IH) is a rare central disorder of hypersomnolence characterized by excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia.
Yves Dauvilliers, S. Chenini, Ophélie Thobois, A. Rassu, C. Denis, Lily Guiraud, I. Jaussent, L. Barateau   +7 more
semanticscholar   +1 more source

Weight changes during treatment with low-sodium oxybate in two phase 3 clinical studies in participants with narcolepsy or idiopathic hypersomnia.

Sleep Medicine
OBJECTIVE Low-sodium oxybate (LXB) is approved in the United States for treating cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy and idiopathic hypersomnia in adults.
N. Foldvary-Schaefer, Roman Skowroński, P. Chandler, Douglas S Fuller, T. Steininger, Thomas Measey, S. Candler, Marisa Whalen, Y. Dauvilliers   +8 more
semanticscholar   +1 more source

0856 Real-World Patient Insights on Low-Sodium Oxybate for Idiopathic Hypersomnia: Interim Results from LYRICAL

Sleep
Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia (IH).
C. Drachenberg, J. Cline, Jennifer D’Souza, Christina Graham, Emily Kim, Meaghan Lawrence, Meagan Farrell, Grecia Sanchez, Donald Stull, M. Whalen, Jessica K Alexander, Laura Herpel   +11 more
semanticscholar   +1 more source

Current knowledge on the pathophysiology of idiopathic hypersomnia and potential mechanisms of action for low-sodium oxybate treatment

Journal of Clinical Sleep Medicine (JCSM)
We sought to elucidate hypotheses for the pathophysiology of idiopathic hypersomnia and discuss the mechanisms by which low-sodium oxybate (LXB) improves idiopathic hypersomnia symptoms. Published literature on idiopathic hypersomnia sleep abnormalities,
Logan D Schneider, A. Cairns, Chad Ruoff, R. Bogan   +3 more
semanticscholar   +1 more source

0858 Real-World Experience and Satisfaction with Low-Sodium Oxybate in Narcolepsy: Interim Results from LYRICAL

Sleep
Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat excessive daytime sleepiness (EDS) or cataplexy in patients ≥7 years of age with narcolepsy and adults with idiopathic hypersomnia.
C. Drachenberg, J. Cline, Jennifer D’Souza, Christina Graham, Emily Kim, Meaghan Lawrence, Meagan Farrell, Grecia Sanchez, Donald Stull, M. Whalen, Jessica K Alexander, Laura Herpel   +11 more
semanticscholar   +1 more source

0833 Long-Term Safety and Tolerability of Once-Nightly Sodium Oxybate: A Post Hoc Analysis from RESTORE

Sleep
Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations. RESTORE (NCT04451668)
S. Ibrahim, John R. Harsh, Bruce C. Corser, J. Hudson, Adrian Santamaria, Paula Schweitzer, B. Abaluck, J. Gudeman   +7 more
semanticscholar   +1 more source

Sodium oxybate versus midazolam for end-of-life continuous deep sedation: a randomised controlled trial

BMJ Supportive & Palliative Care
Objective At the end of life, some patients with refractory suffering require deep continuous sedation. Based on the pharmacological properties, we hypothesised that sodium oxybate may offer advantages in these particular situations by preventing ...
J. Ciais, Pierre-Henri Jacquin, Amélie Gac Marrec, Alexiane Decorbez, Gaëtan Saudemont, C. Dugourd, F. Berthier, D. Payen   +7 more
semanticscholar   +1 more source

Sodium oxybate

Reactions Weekly, 2017
  +7 more sources

0831 Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Results from the DUET Study

Sleep
Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) assessing the effectiveness of low-sodium oxybate (LXB ...
Logan D Schneider, Chad Ruoff, D. Plante, Deborah A. Nichols, T. Steininger, D. Fuller, M. Kirby, Sarah Akerman, Jessica K Alexander, M. Whalen, A. Cairns   +10 more
semanticscholar   +1 more source

0860 Subjective Sleep Quality with Low-Sodium Oxybate Treatment in Narcolepsy: Results from the DUET Study

Sleep
Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, multiple-cohort, open-label study (NCT05875974) evaluating the effectiveness of low-sodium oxybate (LXB ...
R. Sangal, Emmanuel Mignot, Chad Ruoff, Deborah A. Nichols, T. Steininger, D. Fuller, M. Kirby, M. Whalen, Logan D Schneider   +8 more
semanticscholar   +1 more source